v3.26.1
Segment Information
3 Months Ended
Mar. 28, 2026
Segment Reporting [Abstract]  
Segment Information

Note 21: Segment Information

 

The Company operates within targeted markets through three reportable segments for continuing operations: Fintech, Biotech, and Corporate and Other. The Biotech segment is being presented as discontinued operations for the 13 weeks ended March 28, 2026 and March 29, 2025 (see Note 4).

 

The following tables present the Company’s segment information for the 13 weeks ended March 28, 2026 and March 29, 2025 (in $000’s):

 

 Schedule of Segment Information

       
   Thirteen Weeks Ended 
   March 28, 2026   March 29, 2025 
Revenues          
Fintech  $4,712   $4,849 
Biotech (Discontinued operations)        
Corporate and other        
Total Revenues  $4,712   $4,849 
Gross profit          
Fintech  $3,574   $1,926 
Biotech (Discontinued operations)        
Corporate and other        
Total Gross profit  $3,574   $1,926 
Operating loss          
Fintech  $(1,638)  $(138)
Biotech (Discontinued operations)   (177)   (540)
Corporate and other   (1,105)   (1,268)
Total Operating loss  $(2,920)  $(1,946)
Depreciation and amortization          
Fintech  $888   $728 
Biotech (Discontinued operations)       482 
Corporate and other        
Total Depreciation and amortization  $888   $1,210 
Interest (expense) income, net          
Fintech  $(379)  $(376)
Biotech (Discontinued operations)        
Corporate and other   (127)   (344)
Total Interest (expense) income, net  $(506)  $(720)
Net income (loss) before income taxes          
Fintech  $1,631   $543 
Biotech (Discontinued operations)   (177)   (540)
Corporate and other   (358,028)   (1,690)
Total Net income (loss) before income taxes  $(356,574)  $(1,687)